{
    "organizations": [],
    "uuid": "8262c7a57d7911ea2b19679015d67eec9a8f8703",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ocular-therapeutix-announces-propo/brief-ocular-therapeutix-announces-proposed-public-offering-of-common-stock-idUSASB0C26J",
    "ord_in_thread": 0,
    "title": "BRIEF-Ocular Therapeutix Announces Proposed Public Offering Of Common Stock",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 24 (Reuters) - Ocular Therapeutix Inc:\n* OCULAR THERAPEUTIXâ„¢ ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK\n* OCULAR THERAPEUTIX - TO USE PROCEEDS FROM OFFERING, EXISTING CASH AND EQUIVALENTS, TO FUND PLANNED RESUBMISSION OF NEW DRUG APPLICATION FOR DEXTENZA\n* OCULAR THERAPEUTIX - TO ALSO USE PROCEEDS TO FUND CLINICAL DEVELOPMENT OF OTX-TP, OTX-TIC AND OTX-TKI, ADDITIONAL PRECLINICAL, REGULATORY ACTIVITIES Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-25T05:19:00.000+02:00",
    "crawled": "2018-01-25T13:18:59.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "ocular",
        "therapeutix",
        "inc",
        "ocular",
        "announces",
        "proposed",
        "public",
        "offering",
        "common",
        "stock",
        "ocular",
        "therapeutix",
        "use",
        "proceeds",
        "offering",
        "existing",
        "cash",
        "equivalent",
        "fund",
        "planned",
        "resubmission",
        "new",
        "drug",
        "application",
        "dextenza",
        "ocular",
        "therapeutix",
        "also",
        "use",
        "proceeds",
        "fund",
        "clinical",
        "development",
        "additional",
        "preclinical",
        "regulatory",
        "activity",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}